Authors
Latest:
UnitedHealth’s Acquisition of PBM Catamaran Heralds Escalating Price War With DrugmakersLast week’s announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager (PBM) Catamaran for $12.8 billion officially puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Michael Griffith.
Latest:
Fake Medications, Real SolutionsTactics pharma leaders can implement to stem the continued global threat of counterfeit drugs.
Latest:
HBA's Woman of the Year 2017For Bahija Jallal, chosen this year's Healthcare Businesswomen’s Association Woman of the Year, a passion for translational science has been the central guide in a career rise from cancer researcher to leading a big pharma biotech engine.
Latest:
Patent Strategy Implications in the Biosimilars SpaceColleen Tracy James and Neil DuChez ask, is biosimilar litigation the new frontier as predicted or an area pursued less vigorously as under the Hatch-Waxman Act because of cost and manufacturing obstacles?
Latest:
Accent on AccessibilityProgram provides effective, cost-efficient way to help patients overcome affordability barriers and obtain the critical medicines they need.
Latest:
Should You Outsource Analytics?Successful outsourcing can provide pharma companies with high-value, cost-effective analytics. But there are many challenges to overcome, write Ram Moorthy and Dharmendra Sahay.
Latest:
The Growing Importance of Real World DataStakeholders around the world can benefit from RWD as it can improve patient outcomes and speed at which products come to market.
Latest:
Pharma Transparency in Brazil: Latest DevelopmentsScott Lewin looks at Brazil's recently expanded transparency inititatives and how they affect pharma companies doing business in the region.
Latest:
Relationship-Centric Technology: Improving the Human Experience for Better EngagementRelationship-centric technology presents a sizable emerging opportunity for sponsors to improve the performance of clinical development, writes Tom O' Leary.
Latest:
Opposites Attract: Pairing R&D and Commercial TeamsMeike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.
Latest:
Multiethnic Marketing: The Billion-Dollar UpsideTapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.
Latest:
Patient Adherence: Balancing High-Tech with High-TouchLoreen M. Brown discusses how technology has influenced how healthcare teams function, from leveraging and delivering care to interacting with patients throughout the patient journey.
Latest:
"There's a Cure for That..."Cures and therapies with curative intent are here in hepatitis C and are coming in other serious diseases. So everyone, from pharma suppliers patients, is scrambling to figure out what this means, writes Mike Rutstein.
Latest:
Big Data's Big Opportunity in ChinaBryan Spielman outlines why China is poised for a data renaissance-one that could play a pivotal role in the next wave of pharma innovation.
Latest:
Taking Flight: Pharm Exec's Top 50 Pharma Companies 2015Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.
Latest:
Blockbuster 2.0: Eight Ways to Follow that LeaderWhat can companies do for an encore when their own blockbuster product is threatened by branded or generic competitors?
Latest:
Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug AdherenceDrug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority
Latest:
Sales Personnel Contracts, Sword or Shield for M&A ValuationDetermining a company’s acquisition/merger value requires an intensive due diligence process. Attorney Gregg Metzger discusses salesforce contracts which, especially for life science companies, cannot be overlooked.
Latest:
Big Data Innovation and Risk: How to Strike the BalanceAs the industry continues to face declining R&D productivity, one efficient way of making the failure rate lower is to use data, writes Adam Towvim.
Latest:
Confronting the Post-Grant ThreatChallenges from investment firms to biopharma patents spur the industry to action to protect its drug franchises
Latest:
Towards Real-World Patient CentricityPatient centricity requires clinical trials to be based on life outside the lab, writes Mads Holme.
